Vanguard Group’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-14,317
| Closed | -$7.57K | – | 4374 |
|
|
2025
Q1 | $7.57K | Sell |
14,317
-2
| -0% | -$3 | ﹤0.01% | 4263 |
|
|
2024
Q4 | $75.3K | Sell |
14,319
-17,053
| -54% | -$112K | ﹤0.01% | 4186 |
|
|
2024
Q3 | $449K | Hold |
31,372
| – | – | ﹤0.01% | 4001 |
|
|
2024
Q2 | $508K | Sell |
31,372
-1,978
| -6% | -$49.6K | ﹤0.01% | 3996 |
|
|
2024
Q1 | $3.37M | Buy |
33,350
+7,679
| +30% | +$485K | ﹤0.01% | 3433 |
|
|
2023
Q4 | $606K | Hold |
25,671
| – | – | ﹤0.01% | 3977 |
|
|
2023
Q3 | $519K | Sell |
25,671
-342
| -1% | -$6.63K | ﹤0.01% | 4042 |
|
|
2023
Q2 | $676K | Hold |
26,013
| – | – | ﹤0.01% | 4026 |
|
|
2023
Q1 | $541K | Hold |
26,013
| – | – | ﹤0.01% | 4107 |
|
|
2022
Q4 | $531K | Sell |
26,013
-95
| -0.4% | -$1.79K | ﹤0.01% | 4081 |
|
|
2022
Q3 | $720K | Sell |
26,108
-2,863
| -10% | -$82.4K | ﹤0.01% | 4101 |
|
|
2022
Q2 | $765K | Sell |
28,971
-4,330
| -13% | -$193K | ﹤0.01% | 4172 |
|
|
2022
Q1 | $2.66M | Buy |
33,301
+583
| +2% | +$72K | ﹤0.01% | 3834 |
|
|
2021
Q4 | $6.67M | Buy |
32,718
+5,966
| +22% | +$1.49M | ﹤0.01% | 3450 |
|
|
2021
Q3 | $8.65M | Buy |
26,752
+2,749
| +11% | +$802K | ﹤0.01% | 3335 |
|
|
2021
Q2 | $6.24M | Buy |
24,003
+4,504
| +23% | +$1.37M | ﹤0.01% | 3475 |
|
|
2021
Q1 | $7.53M | Buy |
+19,499
| New | +$7.87M | ﹤0.01% | 3315 |
|
Other funds holding VINC
Vanguard Group's VINC Position: Q2 2025 in Review
Vanguard Group sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 14,317 shares — an estimated $7.57K sold.
Vanguard Group first reported a position in VINC in Q1 2021 and held it in 17 quarters. The position peaked at $8.65M in Q3 2021. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.
- Vanguard Group reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Vanguard Group sold 14,317 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $7.57K.
- Vanguard Group first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 17 quarters.
- Vanguard Group's Vincerx Pharma, Inc. Common Stock position peaked at $8.65M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.
Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.